Learning Together: Incorporating Latest Melanoma Data in First-Line Treatment Decision-Making
Navigating frontline therapy for advanced, unresectable, or metastatic cutaneous melanoma requires balancing long-term survival outcomes with toxicity profiles and patient quality of life. In the absence of direct randomized trials comparing all contemporary regimens, clinicians must rely on mature long-term data to guide personalized treatment selection.
This educational offering combines an accredited on-demand webinar and an evidence-based clinical infographic detailing the latest 5-year data from landmark clinical trials. Together, these resources translate complex survival curves, response durability, and safety endpoints into actionable guidance for frontline patient care.
Webinar
Learning Together: Incorporating Latest Melanoma Data in First-Line Treatment Decision-Making
Companion Infographic
RELATIVITY-047 5-Year Update: Nivolumab + Relatlimab in Advanced Melanoma
This program has been made possible through unrestricted support from Bristol-Myers Squibb.